Pediatric Praziquantel Consortium

Performance Materials at Merck KGaA, Darmstadt, Germany: Key Player towards the success of the Consortium Pediatric Praziquantel Program

13 September 2018

The broad contribution by Merck KGaA, Darmstadt, Germany to the Pediatric Praziquantel Consortium includes the...

Nature reviews publication: Global overview of schistosomiasis research and control

31 August 2018

While considerable progress has been made to control schistosomiasis, challenges remain as there is no vaccine...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie


Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more